Clinical Trial Update: Treatment of Idiopathic Thrombocytopenic Purpura (ITP) With Subcutaneously Administered Anti-D [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating subcutaneously administered Anti-D for idiopathic thrombocytopenic purpura has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Thrombocytopenic Purpura

Drugs mentioned

• Anti-D (Rho(D) immune globulin)

Snippet

Sponsor: University of Aarhus | Conditions: Idiopathic Thrombocytopenic Purpura | Phase 2 | Status: COMPLETED